Samuel Waxman Cancer Research Foundation Appoints Dr. Robert Hromas, Chair of Medicine at University of Florida Health, to its Scientific Advisory Board
|Robert Hromas, M.D.|
New York, NY, February 2, 2016 – The Samuel Waxman Cancer Research Foundation (SWCRF) today announced the addition of distinguished cancer researcher Robert Hromas, M.D., Chair of Medicine at University of Florida Health, to its scientific advisory board (SAB). Dr. Hromas, who continues his position at the University of Florida Health, will join his fellow SWCRF SAB members at the Waxman Foundation’s scientific review and symposium on May 1-2 to evaluate progress reports from the foundation’s funded researchers as part of the SWCRF’s annual grant renewal process.
“We are most pleased to welcome Rob Hromas to our scientific advisory board,” said SWCRF founder and CEO Samuel Waxman, M.D. “He has a multifaceted background in cancer research, patient care and academia that will be an asset to the SAB’s evaluation of our grantees’ work at the upcoming scientific review.”
The SWCRF SAB, together with the foundation’s scientific leaders, approves grant proposals submitted by scientists with NCI-approved research programs. The board includes Steven D. Gore, M.D., Director of Hematologic Malignancies at Yale Cancer Center and Clinical Program Leader for Hematology at Smilow Cancer Hospital at Yale-New Haven, Lorraine Gudas, Ph.D., Chair of Pharmacology at Weill Cornell Medical Center, Ramon Parsons, M.D., Ph.D., Professor and Chair of Oncological Sciences at the Icahn School of Medicine at Mount Sinai, Nancy Speck, Ph.D., Professor of Cell and Developmental Biology at the University of Pennsylvania, and Hua Yu, Ph.D., Professor of Cancer Immunotherapeutics and Tumor Immunology, City of Hope NCI Comprehensive Cancer Center.
The SWCRF’s scientific leadership includes Samuel Waxman, M.D., Founder and CEO, Jonathan D. Licht, M.D., Director of the University of Florida Health Center, who is SWCRF’s Chief Scientific Officer, and Alan G. Rosmarin, M.D., Chief of Hematology/Oncology at UMass Memorial Cancer Center of Excellence, who is SWCRF’s Chief Mission Officer.
Scheduled for May 1 and 2 at the Leon and Norma Hess Center for Science and Medicine at The Mount Sinai Hospital, the SWCRF’s annual scientific review and symposium brings together the Institute Without Walls, a network of the foundation’s funded scientists working collaboratively throughout the United States and abroad on research projects that identify and correct abnormal gene function that causes cancer. This research is the basis for developing minimally toxic treatments for patients. The network includes scientists from leading cancer research institutions, including Dana-Farber Cancer Institute, Johns Hopkins University, Memorial Sloan-Kettering Cancer Center, Icahn School of Medicine at Mount Sinai and Weill Cornell Medical Center, among many others.
About Robert Hromas, M.D.
Dr. Hromas is the Chair of Medicine at University of Florida Health, where he is also Vice President of the University of Florida Physicians Clinical Practice Association, and a member of the UF Health Executive Board. He has published over 150 medical research papers, been continuously NIH funded for over two decades, and has chaired multiple NIH and ACS study sections. He has trained 27 graduate students or fellows, most of which have entered academic careers, and 20 junior faculty, almost all of which have obtained tenure. He has served on editorial boards of Blood and Stem Cells. He has won numerous teaching and patient care awards, including the Indiana University Humanism in Medical Education Award, Indiana University Board of Trustees Outstanding Teacher Award, and the People Living Through Cancer Caring Award. He has been Chair of Scientific Affairs for the American Society of Hematology, and their congressional and media representative. He has isolated and characterized multiple hematopoietic transcription factors, chemokines and cytokines, and leukemia translocations. He isolated the first functional human transposase, and demonstrated that it was critical to DNA replication and repair. He has identified a novel component of Homologous Recombination DNA repair that is the key decision point for DNA repair pathway choice. He created and currently leads a public-private drug development consortium that targets the addiction of cancer cells to DNA repair in order to replicate. For these and other accomplishments he has been elected to the American Society of Clinical Investigation, Association of Professors of Medicine, and Association of American Physicians.
About Samuel Waxman Cancer Research Foundation
The Samuel Waxman Cancer Research Foundation is an international organization dedicated to curing and preventing cancer. The Foundation is a pioneer in cancer research and its mission is to eradicate cancer by funding cutting-edge research that identifies and corrects abnormal gene function that causes cancer. This research is the basis of developing minimally toxic treatments for patients. Through the Foundation’s collaborative group of world-class scientists, the Institute Without Walls, investigators share information and tools to speed the pace of cancer research. Since its inception in 1976, the Samuel Waxman Cancer Research Foundation has awarded approximately $90 million to support the work of more than 200 researchers across the globe. For more information, visit: www.waxmancancer.org.
Director, Marketing & Communications
Samuel Waxman Cancer Research Foundation